

YMTHE, Volume 25


## **Supplemental Information**

### **Exosome-Mediated miR-155 Transfer from Smooth Muscle Cells to Endothelial Cells Induces Endothelial Injury and Promotes Atherosclerosis**


**Bin Zheng, Wei-na Yin, Toru Suzuki, Xin-hua Zhang, Yu Zhang, Li-li Song, Li-shuang  
Jin, Hong Zhan, Hong Zhang, Jin-shui Li, and Jin-kun Wen**

## Supplemental material


A




B




C



D






**Figure 1. KLF5 regulates expression of miRNAs, particularly miR-155**

A, Representative photographs of immunofluorescence staining with KLF5 staining, CD 31 and SM  $\alpha$ -actin in carotid artery of KLF5<sup>Tgln<sup>-/-</sup></sup> mice and KLF5<sup>WT</sup> mice. Magnification,  $\times 100$  (KLF5, SM  $\alpha$ -actin staining and CD31 staining). B, KLF5 expression was detected by Western Blot (n=3) in different tissues of KLF5 in KLF5<sup>Tgln<sup>-/-</sup></sup> (VSMC-specific knockout of KLF5) mice and KLF5<sup>WT</sup> mice. C, HASMCs were transfected with pAd or pAd-KLF5 for 48 h. KLF5 expression was detected by Western blotting (n=3). \*\*P<0.01 vs pAd group. D, HASMCs were transfected with pAd or pAd-KLF5 for different times. miRNA expression was detected by real-time PCR (n=6). \*P<0.05 vs 0 h group. #P<0.05 vs 0 h group. E, HASMCs were treated with oxLDL for 24 h. KLF5 mRNA expression was detected by Real-time PCR (n=6). \*P<0.05 vs con group. \*\*P<0.01 vs con group. F, HASMCs were treated with oxLDL for different times. miRNA expression was detected by real-time PCR (n=6). \*P<0.05 vs 0 h group. #P<0.05 vs 0 h group.

Figure 2




**Figure 2. KLF5 induces enrichment of miR-155 in extracellular vesicles**

A, Electron microscopy image of an isolated vesicle. B, Exosomes was extracted from the medium of VSMCs by ultracentrifuge. CD63 expression in exosomes was detected by Western Blotting (n=6). C, Exosomes were extracted from the medium of

VSMCs by ultracentrifuge. Cells were lysed and cell lysate was harvested. 20  $\mu$ g protein was used to detect the expression of KLF5 and CD63 in exosomes by Western Blotting (n=3). D, miR-155 levels were detected by real-time PCR (n=6) in the remaining supernatant of exosomes from the medium of VSMCs. \*P<0.05 vs pAd group. E, Part of ~2500 bp upstream sequence of pri-miR-155. KLF5 binding site was marked with underline (green). Mutated sites of KLF5 binding site was marked with underline (red). F, Reporter gene assay using miR-155 mutation promoter (n=6). VSMCs were transfected with indicated vectors for 48 h, luciferase activities were measured with the Dual-Luciferase Reporter System (Promega). Results are means $\pm$ S.E.M. for six separate transfection assays with duplicate plates. \*P <0.05 vs vehicle group.



Figure 3




**Figure 3 KLF5 affects the transmission of miR-155 between HASMCs and endothelial cells**

An in vitro co-culture system was used where HASMCs are seeded in the top compartment, which is separated by a porous membrane from endothelial cells that are cultured in the bottom compartment. HASMCs (top compartment) were transfected with FITC-miR-155 together with indicated virus or siRNA and treated with or without oxLDL and co-cultured with endothelial cells (bottom compartment). FITC-miR-155 (green) and CD 31 expression (red) in endothelial cells was analyzed by confocal microscopy.



Figure 4  
A




**B**




**C**



**D**








**Figure 4. Vascular-derived miR-155 is transported to endothelial cells, leading to cellular dysfunction**

A, Exosomes secreted by pAd- or pAd-KLF5-transduced HASMCs were intravenously injected into the tail vein of apoE<sup>-/-</sup> mice fed with HFD (n = 6) once a week. Representative photographs of miR-155 in situ hybridization (green) and mac-2 staining (red), SM  $\alpha$ -actin staining (red), respectively. B, MTS assay was used to detect the proliferation of endothelial cells. \*\*P <0.01 vs con exosome or miR-155-rich+anti-con group. C, Wound-healing assay was used to detect the migration of endothelial cells. \*P <0.05 vs con exosome or miR-155-rich+anti-con group. D, Tube formation assay was used to detect the function of endothelial cells. E, An in vitro co-culture system was used where HASMCs were seeded in the top compartment, which is separated by a porous membrane from endothelial cells that are cultured in the bottom compartment. HASMCs (top compartment) were transfected with indicated mimic or inhibitor together with indicated virus and co-cultured with endothelial cells (bottom compartment). MTS assay was used to detect the proliferation of endothelial cells. \*P <0.05 vs con mimic group or con mimic+pAd-KLF5 group, respectively. #P <0.05 vs anti-con group or anti-con+pAd-KLF5 group, respectively. F, Wound-healing assay was used to detect the migration of endothelial cells. \*P <0.05 vs con mimic group or con

mimic+pAd-KLF5 group, respectively. #P <0.05 vs anti-con group or anti-con+pAd-KLF5 group, respectively.


Figure 5




**Figure 5. miR-155 regulates endothelial barrier function**


pAd or pAd-KLF5 were intravenously injected into the tail vein of C57BL/6 mice (n = 6) once a week. Total miRNA from aortic tissue of miR-155<sup>WT</sup> or miR-155<sup>-/-</sup> mice (n=6) were prepared and indicated TJ protein mRNA were detected by real-time PCR. \*p< 0.05 vs pAd group; #p< 0.05 vs miR-155<sup>WT</sup> group.

Figure 6  
A



B






### Figure 6. miR-155 inhibition suppresses atherogenesis

A, Representative photographs of staining of miR-155 by FISH in carotid artery of apoE<sup>-/-</sup> mice fed with HFD for 4 weeks, 6 weeks or 8 weeks, respectively. Magnification, ×100. B, Representative photographs of en face oil red O-stained thoracic aortas and HE-stained sections of the aortic root of apoE<sup>-/-</sup> or apoE<sup>-/-</sup>miR-155<sup>-/-</sup> mice. C, Endothelial cells were transfected with miR-155 mimics or miR-155 inhibitor (anti-miR-155) for 24 h, and the proliferation of endothelial cells was then detected by MTS assay. \*\*P<0.05 vs con mimic group. \*P<0.05 vs anti-con group. D, Endothelial cells were transfected with miR-155 mimics or miR-155 inhibitor (anti-miR-155) for 24 h, and tube formation assay was performed. E, Endothelial cells were transfected with miR-155 mimics or miR-155 inhibitor (anti-miR-155) for 24 h, and the migration of endothelial cells was then detected by wound-healing assay. \*P<0.05 vs con mimic group. #P<0.05 vs anti-con group.

**Figure 7**



**Figure 7 Inhibition of miR-155 prevents atherogenesis**

Immunofluorescence staining of miR-155(red) and DAPI (blue) in apoE<sup>-/-</sup> mice feed with HFD for 8 weeks.

**Table I. miRNAs detected in HASMCs transfected with pAd or pAd-KLF5 displaying a variation lower than 2 between replicates**

<b>Upregulated miRNAs</b>
hsa-miR-31-5p ; hsa-miR-943 ; hsa-miR-24-3p ; hsa-miR-625-5p ; hsa-miR-4305 ; hsa-miR-3178 ; hsa-miR-1290 ; hsa-miR-4443 ; has-miR-29a-5p ; hsa-miR-4290 ; hsa-miR-638 ; hsa-miR-20b-3p ; hsv1-miR-H7-3p ; hsa-miR-4791 ; hsa-miR-1304-5p ; hsa-miR-935 ; hsa-miR-1285-3p ; hsa-miR-4292 ; hsa-miR-421 ; hsa-miR-4449 ; hsa-miR-665 ; hsa-miR-1273e ; hsa-miR-410-3p ; hsa-miR-502-3p ; hsa-miR-1469 ; hsa-miR-4732-5p ; hsa-miR-1827 ; hsa-miR-1207-3p ; hsa-miR-4644 ; ebv-miR-BART8-3p ; hsa-miR-324-3p ; hsa-miR-3195 ; hsa-miR-4530 ; hsa-miR-454-3p ; hsa-miR-622 ; hsa-miR-493-3p ; hsa-miR-4497 ; hsa-miR-652-3p ; hsa-miR-214-3p ; hsa-miR-199b-5p ; hsa-miR-106a-5p ; hsa-miR-4765 ; hsa-miR-1246 ;

**Table II. miRNAs detected in HASMCs-derived exosomes transfected with pAd or pAd-KLF5 displaying a variation lower than 1.5 between replicates**

<b>Upregulated miRNAs</b>
hsa-miR-381-3p; hsa-miR-4317; hsa-miRPlus-A1073; hsa-miR-26b-5p; hsa-miR-155-5p; hsa-miR-381-5p; hsa-miR-181d-5p; hsa-miR-154-3p; hsa-miR-190a-5p; hsa-miR-335-5p; hsa-miR-1185-1-3p; hsa-miR-320c; hsa-miR-885-5p; hsa-miR-376a-5p; hsa-miR-214-5p; hsa-miR-193a-3p; hsa-miR-543; hsa-miR-500a-5p/hsa-miR-500b-5p; hsa-miR-377-3p; hsa-miR-1207-3p; hsa-miR-26a-5p; hsa-miR-140-3p; hsa-miR-320a; hsa-miR-654-3p; hsa-miR-548t-5p; hsa-miR-5681b; hsv2-miR-H20; hsa-miR-34a-5p; hsa-miR-145-5p; hsa-miR-493-3p; hsa-miR-337-5p; hsa-miR-5571-5p; hsa-miR-432-5p; hsa-miR-143-3p; hsa-miR-154-5p; hsa-miR-551b-3p;